Novartis' Rare Disease Drug Fabhalta Wins FDA Approval for IgAN

On the milestone day of August 8, 2024, the FDA (U.S. Food and Drug Administration) is pleased to announce the formal approval of Fabhalta (iptacopan). A revolutionary drug developed by Novartis Pharmaceuticals, designated for the treatment of immunoglobulin A kidney disease (IgAN). A rare but widespread kidney disease. It is worth noting that Fabatan has previously been approved for the treatment of the extremely rare paroxysmal sleep hemoglobinuria (PNH) in December 2023, and now its breakthrough in the field of IgAN undoubtedly highlights Novartis's outstanding contribution in the field of pharmaceutical innovation.

The approval of Fabhalta, a first complement inhibitor carefully developed by Novartis, is based on its outstanding performance in the accelerated approval process and is specifically tailored for adults with primary IgA nephropathy. IgAN, an insidious but dangerous kidney disease characterized by an abnormal immune system attack on kidney tissue, leading to glomerulitis and proteinuria, has long plagued countless patients. Although existing treatments have alleviated the disease to a certain extent, unfortunately, nearly half of patients will inevitably go to kidney failure within 10 to 20 years after diagnosis, and need to rely on dialysis or kidney transplantation to stay alive.

In the Phase III APPLAUSE IgAN clinical trial led by Novartis, Fabhalta has surprised the audience with its superior efficacy. Compared to placebo, the drug successfully reduced patients' urinary protein-creatinine ratio (UPCR) by a staggering 44% in just 9 months, an effect that was not only clinically significant but also statistically significant (p<0.0001). In particular, Fabhalta's efficacy was highly consistent across patient populations across age, gender, ethnicity and baseline disease characteristics, demonstrating its broad applicability and strong potential as a potential treatment.

The key to Fabhalta's prominence in the treatment of IgAN is its unique mechanism of action - by precisely inhibiting the replacement pathway of the complement system, it effectively blocks a key link in the pathological process of IgAN. This approval not only marks a solid step forward for Novartis in the field of kidney disease treatment, but also indicates the infinite possibilities for the future development of the company's kidney disease pipeline. In addition to Fabhalta, Novartis is also developing other innovative therapies for IgAN, such as atrasentan and zigakibart, in an effort to provide patients with more comprehensive and diverse treatment options.

It is worth mentioning that the application of Fabhalta is not limited to IgAN. At present, the drug is gradually expanding to other rare complement-mediated diseases, such as C3 glomerulonephritis (C3G), atypical hemolytic uremic syndrome (aHUS), immune complex membranous proliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN), showing its broad application prospects as a "master key".

For many IgAN patients, the approval of Fabhalta is undoubtedly a ray of hope. It not only brings new treatment options to patients, but also promises to significantly improve their clinical outcomes and improve their quality of life. At the same time, Novartis is actively promoting the adoption and accessibility of this drug through close cooperation with healthcare companies to ensure that patients can afford this innovative treatment. In addition, the company will increase its efforts to promote Fabhalta and increase awareness and acceptance of the drug among patients and physicians to gradually replace traditional treatments such as glucocorticoids, which have long-term side effects.

In terms of pricing, Novartis decided after deliberation to keep Fabatan's listing price unchanged at $550,000. While the price is higher than the approximately $120,000 wholesale purchase cost of Filspari, Novartis U.S. President Victor Burto said, "We have fully considered all potential indications for this innovative drug and its impact on different disease groups in our pricing." We believe the unique value of Fabatane and the significant benefits it provides to patients will fully justify its price."

In addition, Fabatane also shows significant advantages in the convenience of medication. Unlike Filspari, patients taking Fabatam do not have to discontinue regular medications such as angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-II receptor antagonists (ARBs), nor do they have to regularly monitor liver function as with Filspari. Novartis said that with its unique drug mechanism and good safety record, Farbactam may be more suitable for certain types of IgAN patient groups.

Going forward, Novartis will continue to focus on the development and marketing of innovative medicines for rare kidney diseases. Through close partnerships with medical institutions, research institutions and patient organizations worldwide, Novartis will continue to promote the advancement and development of the treatment of kidney disease to bring benefits to more patients in need of new therapies.